Silco Pharmaceuticals Limited (DSE:SILCOPHL)

Market Cap	1.49B -14.3%
Revenue (ttm)	431.04M +0.3%
Net Income	42.40M -15.1%
EPS	0.41 -14.8%
Shares Out	103.81M
PE Ratio	35.10
Forward PE	n/a
Dividend	0.11 (0.76%)
Ex-Dividend Date	Dec 17, 2025

Volume	589,691
Average Volume	925,866
Open	14.60
Previous Close	14.60
Day's Range	14.30 - 14.70
52-Week Range	11.10 - 18.50
Beta	0.23
RSI	51.57
Earnings Date	Apr 28, 2026

About Silco Pharmaceuticals

Silco Pharmaceuticals Limited engages in manufacturing and marketing of finished pharmaceutical products in Bangladesh and internationally. It offers products in the therapeutic areas of analgesic and antipyretic, anti-platelet, antiasthmatic, antibiotic, antidepressant, antidiabetic, antiemetic, antifungal, antihistamin, antihypertensive and antianginal, antimicrobial, antiprotozoal, antispasmodic, antiulcerant, anxiolytic, calcium and combinations, central muscle relaxants, diuretics, gastroprokinetic, haematinic, vitamins and minerals, laxat...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 313
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SILCOPHL

Financial Performance

In fiscal year 2025, Silco Pharmaceuticals's revenue was 431.54 million, an increase of 5.23% compared to the previous year's 410.10 million. Earnings were 42.65 million, a decrease of -7.04%.